ParkinsonCanadaV1, Main, Exploration, bibRecord, 002F51

Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease

Identifieur interne : 002F51 ( Main/Exploration ); précédent : 002F50; suivant : 002F52

Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease

Auteurs : D. J. Brooks [Royaume-Uni] ; K. A. Frey [États-Unis] ; K. L. Marek [États-Unis] ; D. Cakes [États-Unis] ; D. Paty [Canada] ; R. Prentice [États-Unis] ; C. W. Shults [États-Unis] ; A. J. Stoessl [Canada]

Source :

Experimental neurology : (Print) [ 0014-4886 ] ; 2003.

RBID : Pascal:04-0340292

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Technique, Développement, Dégénérescence, Traitement, Homme, Système nerveux pathologie, Incertitude, Aptitude, Evaluation, Voie abord, Neurotransmission, Axone, Changement médicament, Lévodopa, Dopamine, Decarboxylase, Fluorodopa(18F), Tomoscintigraphie émission monophotonique, Positon, Stockage, Vésicule synaptique, Transporteur vésiculaire monoamine.
Wicri :
- topic : Homme, Stockage.

English descriptors

KwdEn :
- Ability, Axon, Decarboxylase, Degeneration, Development, Dopamine, Drug conversion, Evaluation, Fluorodopa(18F), Human, Levodopa, Nervous system diseases, Neurotransmission, Parkinson disease, Positron, Single photon emission tomography, Storage, Surgical approach, Synaptic vesicle, Technique, Treatment, Uncertainty, Vesicular monoamine transporter.

Abstract

A major goal of research in Parkinson's disease (PD) has been the development of treatments to slow the progressive degeneration of the nigrostriatal dopaminergic system and to reduce the functional decline of patients. Because of the uncertainty in the ability of the clinical evaluation to reflect the status of the nigrostriatal dopaminergic system once dopaminergic therapy has commenced, investigators in PD have sought to develop alternative measures of disease. One approach, which has been extensively explored, is neuroimaging with radiotracers that interact with processes central to dopaminergic neurotransmission in the nigrostriatal dopaminergic axons-conversion of levodopa to dopamine through aromatic amino acid decarboxylase (AADC), [¹⁸F]fluorodopa PET, storage of dopamine in synaptic vesicles via the vesicular monoamine transporter 2 (VMAT2), (+)-[¹¹C]dihydrotetrabenazine PET, and reuptake of dopamine into axons via the dopamine transporter (DAT), [¹²³I]β-CIT SPECT, and a number of other PET and SPECT ligands. During the 54^th Annual Meeting of the American Academy of Neurology, a group of investigators active in the fields of biomakers, neuroimaging, and neuroprotection met to review the three techniques mentioned above. Prior to the meeting, the participants developed consensus on a set of 10 criteria for a neuroimaging technique to be considered adequate as a biomarker for progression of PD and levels at which the available data for each technique indicate that the criterion was met. The criteria and each of the three imaging techniques mentioned above were reviewed, and the results of that meeting are presented.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000995
to stream PascalFrancis, to step Curation: 000328
to stream PascalFrancis, to step Checkpoint: 000975
to stream Main, to step Merge: 003361
to stream Main, to step Curation: 002F51

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease</title>
<author><name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D. J." last="Brooks">D. J. Brooks</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MRC Faculty of Medicine, Imperial College</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frey, K A" sort="Frey, K A" uniqKey="Frey K" first="K. A." last="Frey">K. A. Frey</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Departments of Neurology and Radiology, University of Michigan</s1>
<s2>Ann Arbor, MI</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Ann Arbor, MI</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marek, K L" sort="Marek, K L" uniqKey="Marek K" first="K. L." last="Marek">K. L. Marek</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institute for Neurodegenerative Disorders</s1>
<s2>New Haven, CT</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Institute for Neurodegenerative Disorders</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cakes, D" sort="Cakes, D" uniqKey="Cakes D" first="D." last="Cakes">D. Cakes</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Biostatistics, University of Rochester</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Rochester, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Paty, D" sort="Paty, D" uniqKey="Paty D" first="D." last="Paty">D. Paty</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Prentice, R" sort="Prentice, R" uniqKey="Prentice R" first="R." last="Prentice">R. Prentice</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Fred Hutchison Cancer Research Center</s1>
<s2>Seattle, WA</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Fred Hutchison Cancer Research Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shults, C W" sort="Shults, C W" uniqKey="Shults C" first="C. W." last="Shults">C. W. Shults</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Neurosciences, University of California, San Diego and VA Medical Center</s1>
<s2>San Diego, CA</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>San Diego, CA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A. J." last="Stoessl">A. J. Stoessl</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Pacific Parkinsons Research Centre, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, British Columbia</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0340292</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 04-0340292 INIST</idno>
<idno type="RBID">Pascal:04-0340292</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000995</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000328</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000975</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000975</idno>
<idno type="wicri:doubleKey">0014-4886:2003:Brooks D:assessment:of:neuroimaging</idno>
<idno type="wicri:Area/Main/Merge">003361</idno>
<idno type="wicri:Area/Main/Curation">002F51</idno>
<idno type="wicri:Area/Main/Exploration">002F51</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease</title>
<author><name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D. J." last="Brooks">D. J. Brooks</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>MRC Faculty of Medicine, Imperial College</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frey, K A" sort="Frey, K A" uniqKey="Frey K" first="K. A." last="Frey">K. A. Frey</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Departments of Neurology and Radiology, University of Michigan</s1>
<s2>Ann Arbor, MI</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Ann Arbor, MI</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marek, K L" sort="Marek, K L" uniqKey="Marek K" first="K. L." last="Marek">K. L. Marek</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institute for Neurodegenerative Disorders</s1>
<s2>New Haven, CT</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Institute for Neurodegenerative Disorders</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cakes, D" sort="Cakes, D" uniqKey="Cakes D" first="D." last="Cakes">D. Cakes</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Biostatistics, University of Rochester</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Rochester, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Paty, D" sort="Paty, D" uniqKey="Paty D" first="D." last="Paty">D. Paty</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Prentice, R" sort="Prentice, R" uniqKey="Prentice R" first="R." last="Prentice">R. Prentice</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Fred Hutchison Cancer Research Center</s1>
<s2>Seattle, WA</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Fred Hutchison Cancer Research Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shults, C W" sort="Shults, C W" uniqKey="Shults C" first="C. W." last="Shults">C. W. Shults</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Neurosciences, University of California, San Diego and VA Medical Center</s1>
<s2>San Diego, CA</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>San Diego, CA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A. J." last="Stoessl">A. J. Stoessl</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Pacific Parkinsons Research Centre, University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, British Columbia</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Experimental neurology : (Print)</title>
<title level="j" type="abbreviated">Exp. neurol. : (Print)</title>
<idno type="ISSN">0014-4886</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Experimental neurology : (Print)</title>
<title level="j" type="abbreviated">Exp. neurol. : (Print)</title>
<idno type="ISSN">0014-4886</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ability</term>
<term>Axon</term>
<term>Decarboxylase</term>
<term>Degeneration</term>
<term>Development</term>
<term>Dopamine</term>
<term>Drug conversion</term>
<term>Evaluation</term>
<term>Fluorodopa(18F)</term>
<term>Human</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Neurotransmission</term>
<term>Parkinson disease</term>
<term>Positron</term>
<term>Single photon emission tomography</term>
<term>Storage</term>
<term>Surgical approach</term>
<term>Synaptic vesicle</term>
<term>Technique</term>
<term>Treatment</term>
<term>Uncertainty</term>
<term>Vesicular monoamine transporter</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Technique</term>
<term>Développement</term>
<term>Dégénérescence</term>
<term>Traitement</term>
<term>Homme</term>
<term>Système nerveux pathologie</term>
<term>Incertitude</term>
<term>Aptitude</term>
<term>Evaluation</term>
<term>Voie abord</term>
<term>Neurotransmission</term>
<term>Axone</term>
<term>Changement médicament</term>
<term>Lévodopa</term>
<term>Dopamine</term>
<term>Decarboxylase</term>
<term>Fluorodopa(18F)</term>
<term>Tomoscintigraphie émission monophotonique</term>
<term>Positon</term>
<term>Stockage</term>
<term>Vésicule synaptique</term>
<term>Transporteur vésiculaire monoamine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Stockage</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A major goal of research in Parkinson's disease (PD) has been the development of treatments to slow the progressive degeneration of the nigrostriatal dopaminergic system and to reduce the functional decline of patients. Because of the uncertainty in the ability of the clinical evaluation to reflect the status of the nigrostriatal dopaminergic system once dopaminergic therapy has commenced, investigators in PD have sought to develop alternative measures of disease. One approach, which has been extensively explored, is neuroimaging with radiotracers that interact with processes central to dopaminergic neurotransmission in the nigrostriatal dopaminergic axons-conversion of levodopa to dopamine through aromatic amino acid decarboxylase (AADC), [<sup>18</sup>
F]fluorodopa PET, storage of dopamine in synaptic vesicles via the vesicular monoamine transporter 2 (VMAT2), (+)-[<sup>11</sup>
C]dihydrotetrabenazine PET, and reuptake of dopamine into axons via the dopamine transporter (DAT), [<sup>123</sup>
I]β-CIT SPECT, and a number of other PET and SPECT ligands. During the 54<sup>th</sup>
 Annual Meeting of the American Academy of Neurology, a group of investigators active in the fields of biomakers, neuroimaging, and neuroprotection met to review the three techniques mentioned above. Prior to the meeting, the participants developed consensus on a set of 10 criteria for a neuroimaging technique to be considered adequate as a biomarker for progression of PD and levels at which the available data for each technique indicate that the criterion was met. The criteria and each of the three imaging techniques mentioned above were reviewed, and the results of that meeting are presented.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
</settlement>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D. J." last="Brooks">D. J. Brooks</name>
</region>
</country>
<country name="États-Unis"><noRegion><name sortKey="Frey, K A" sort="Frey, K A" uniqKey="Frey K" first="K. A." last="Frey">K. A. Frey</name>
</noRegion>
<name sortKey="Cakes, D" sort="Cakes, D" uniqKey="Cakes D" first="D." last="Cakes">D. Cakes</name>
<name sortKey="Marek, K L" sort="Marek, K L" uniqKey="Marek K" first="K. L." last="Marek">K. L. Marek</name>
<name sortKey="Prentice, R" sort="Prentice, R" uniqKey="Prentice R" first="R." last="Prentice">R. Prentice</name>
<name sortKey="Shults, C W" sort="Shults, C W" uniqKey="Shults C" first="C. W." last="Shults">C. W. Shults</name>
</country>
<country name="Canada"><noRegion><name sortKey="Paty, D" sort="Paty, D" uniqKey="Paty D" first="D." last="Paty">D. Paty</name>
</noRegion>
<name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A. J." last="Stoessl">A. J. Stoessl</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F51 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F51 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:04-0340292
   |texte=   Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease

Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri